Alexion Pharmaceuticals Company Profile (NASDAQ:ALXN)

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals declared that its board has approved a stock repurchase plan on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 3.4% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's leadership believes its shares are undervalued.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced its quarterly earnings data on Thursday, July, 27th. The company reported $1.56 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.48. The business had revenue of $912 million for the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. Alexion Pharmaceuticals's revenue for the quarter was up 21.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.13 earnings per share. View Alexion Pharmaceuticals' Earnings History.

Alexion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for Alexion Pharmaceuticals.

Alexion Pharmaceuticals updated its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $5.40-5.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.33. The company issued revenue guidance of $3.45-3.53 billion, compared to the consensus revenue estimate of $3.47 billion.

22 brokers have issued twelve-month price objectives for Alexion Pharmaceuticals' stock. Their forecasts range from $120.00 to $182.00. On average, they anticipate Alexion Pharmaceuticals' stock price to reach $155.43 in the next year. View Analyst Ratings for Alexion Pharmaceuticals.

Here are some recent quotes from research analysts about Alexion Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Alexion’s blockbuster drug, Soliris, continues to perform well and the company is working to expand the drug's label. A potential label expansion of the drug for additional indications will boost revenues. Among new products, while Strensiq is doing well, the company redefined its strategy for Kanuma which earlier lagged expectations. In order to focus better in core areas, Alexion is de-prioritizing a few clinical programs and terminating its partnerships with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma. With a new CFO, we expect investor focus on results from the realignment of the resources and Kanuma's performance. Shares of the company have outperformed the industry in the last six months. However, the company relies heavily on Soliris for growth while prcing will impact Strensiq revenues in the second half." (10/2/2017)
• 2. J P Morgan Chase & Co analysts commented, "Additionally, post a series of physician calls in the space, while competitor complement players will have updates in the next 6-18 months, we believe the '1210 profile is already clinically compelling and the burden is on competitors to produce meaningful data," (9/5/2017)
• 3. Morgan Stanley analysts commented, "re-prioritize the strategic direction" of the company. Furthermore, the second-quarter strategic review serves as a "turning point" for investor sentiment."While we understand investor unease that another 'shoe could drop' on this story, we see the risk/reward as compelling and believe new management is making progress right sizing the company and refocusing its efforts," the analyst wrote.2. Underappreciated StoryHarrison also believes Alexion's stock is pricing "little-to-no value" for the ALXN1210 life-cycle extension strategy. Meanwhile, investors are under-appreciating the antibody but the sentiment could turn move positive with potential gMG approval and the release of pivotal data.Harrison also believes Alexion's core asset value is "not impaired." Also, the analyst suggested that the underlying patient need and use of Solaris is "sound" and the company's strategy to protect Solaris through new IP and ALXN1210 is "very defensible with clarity on this strategy coming in less than 12 months." (5/25/2017)
• 4. Barclays PLC analysts commented, "provides support to the patient association in Brazil in the form of unrestricted educational grants and in accordance with local laws and regulations and industry code." In addition, the spokesperson confirmed that Alexion has not been charged with any criminal or civil misconduct.Investors Shrug Barclays' CallShortly after reports of Alexion's raid on Monday, analysts at Barclays offered a quick take on how investors should react.Barclays' Geoff Meacham suggested that while the headline report looks "onerous," the report shouldn't be viewed as a major fundamental concern. The analyst cited "good Soliris growth" (5/9/2017)
• 5. Cowen and Company analysts commented, "We recently hosted investor meetings with CEO Ludwig Hantson, CFO Dave." (4/28/2017)

Some companies that are related to Alexion Pharmaceuticals include BioMarin Pharmaceutical (BMRN), Abcam Plc (ABC), Anika Therapeutics (ANIK), Myovant Sciences Ltd (MYOV), Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Syndax Pharmaceuticals (SNDX), Mirna Therapeutics (SYBX), Strongbridge Biopharma PLC (SBBP), Fortress Biotech (FBIO), Mereo BioPharma Group PLC (MPH), Kamada (KMDA), Kadmon Holdings (KDMN), Peregrine Pharmaceuticals (PPHM), Vericel Corporation (VCEL), MediWound (MDWD) and Alimera Sciences (ALIM).

Alexion Pharmaceuticals' management team includes the folowing people:

• David R. Brennan, Chairman of the Board
• Ludwig N. Hantson Ph.D., Chief Executive Officer, Director
• Paul J. Clancy, Chief Financial Officer
• John B. Moriarty J.D., Executive Vice President, General Counsel
• Martin Mackay Ph.D., Executive Vice President, Global Head - Research and Development
• Julie O'Neill, Executive Vice President - Global Operations
• Edward Miller J.D., Senior Vice President, Global Chief Compliance Officer
• Heidi L. Wagner J.D., Senior Vice President - Global Governmental Affairs
• Brian Goff, Chief Commercial Officer
• Paul A. Friedman M.D., Director

Shares of Alexion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Alexion Pharmaceuticals stock can currently be purchased for approximately $140.84.